Nuwellis, Inc. (NUWE) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Nuwellis, Inc. is a commercial-stage medical device company focused on the Aquadex SmartFlow® system for ultrafiltration therapy to treat fluid overload in adult and pediatric patients. The company operates as a single segment and is headquartered in Eden Prairie, Minnesota.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $1.90 million | $1.86 million |
| Gross Profit | $1.07 million | $1.19 million |
| Gross Margin | 56.0% | 64.1% |
| Operating Loss | $(3.06) million | $(4.75) million |
| Net Loss | $(3.01) million | $(4.33) million |
| Cash and Equivalents (End of Period) | $2.56 million | $1.40 million |
| Operating Cash Flow | $(2.54) million | $(2.86) million |
| Accumulated Deficit | $(301.8) million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2.5% year-over-year, driven by a 4% increase in circuit sales and higher console sales, partially offset by a decline in international sales.
- Margin Compression: Gross margin decreased from 64.1% to 56.0%. This was primarily due to unfavorable manufacturing variances, lower fixed overhead absorption from reduced production volumes, and an obsolete inventory reduction related to the Flex Flow console.
- Expense Reduction: Operating expenses decreased significantly. Selling, General, and Administrative (SG&A) expenses fell 22.3% to $3.58 million, and Research and Development (R&D) expenses dropped 58.8% to $0.55 million. These reductions were driven by decreased headcount, lower compensation costs, and reduced professional service fees following cost-cutting measures implemented in 2024.
- Loss Improvement: Net loss narrowed by approximately 30% compared to the prior year quarter, reflecting the substantial reduction in operating expenses.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for at least twelve months from the filing date. The company has an accumulated deficit of $301.8 million and expects to incur losses in the foreseeable future.
- Liquidity: Management believes existing capital resources are sufficient to support operations through May 31, 2025. The company intends to seek additional capital through debt, equity, or a combination thereof, though there is no assurance of success.
- Strategic Initiatives: In May 2025 (subsequent event), the company finalized an agreement with KDIPrecision Manufacturing to assume assembly responsibilities for key products, aiming to streamline operations and expand manufacturing capabilities.
- Risk Factors: Key risks include potential regulatory actions regarding off-label use of the Aquadex System (specifically for patients under 20 kg), supply chain disruptions from sole-source suppliers, and the impact of U.S. tariff changes on raw materials sourced from China.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, due to two material weaknesses in controls over financial reporting identified in the prior year.
Investor Verification Checklist
- Verify the timeline and terms of the upcoming capital raise required to extend operations beyond May 31, 2025.
- Confirm the status of remediation efforts for the two material weaknesses in internal controls over financial reporting.
- Monitor the impact of the new manufacturing agreement with KDIPrecision on production costs and supply chain reliability.
- Assess the regulatory risk exposure related to off-label use communications and potential FDA enforcement actions.
- Review the specific drivers of the gross margin decline to determine if manufacturing variances are a recurring issue or a one-time inventory adjustment.